Abbott Laboratories Stock Performance
Abbott Laboratories shares closed at $99.60, trading below both key moving averages, with the 50-day moving average at $106.29 and the 200-day moving average at $102.37, per SID market data. The stock has declined 6.41% over the past month and is down 20.92% over the trailing twelve months, reflecting sustained selling pressure across the healthcare sector. ABT's 14-day relative strength index stands at 36.0, approaching oversold territory and signaling persistent bearish momentum. The stock carries a beta of 0.751, indicating lower volatility relative to the broader market, according to Massive/Polygon data. Average daily trading volume registers at approximately 8.88 million shares, while the company maintains a market capitalization of roughly $202.5 billion. The convergence of price action below both moving averages and a depressed RSI reading underscores the current technical weakness facing Abbott shares.
Abbott Laboratories Valuation Analysis
Abbott Laboratories currently trades at a price-to-earnings ratio of 31.15, reflecting a premium valuation relative to broader market averages, per SID market data. The company's PEG ratio stands at -0.58, suggesting that trailing growth metrics do not support the current earnings multiple under conventional PEG analysis frameworks. ABT's price-to-book ratio registers at 3.90, according to SEC filings, positioning the stock at a moderate premium to its net asset value. The company offers a dividend yield of 2.06%, providing income-oriented investors with a steady return component amid the recent share price decline. As a healthcare sector constituent, Abbott's valuation profile reflects the market's pricing of its diversified medical devices, diagnostics, nutrition, and pharmaceutical portfolio. The negative PEG ratio warrants close monitoring as forward earnings estimates evolve, particularly as upcoming quarterly results provide updated growth trajectory data for recalibrating valuation assumptions.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money composite score of 48 out of 100 with a neutral signal, per SID market data. Institutional positioning leads all subcategories with a perfect score of 25 out of 25, indicating robust ownership and conviction among large fund managers reflected in 13F institutional filings. In contrast, the insider trading score sits at 9.3 out of 25, with SEC Form 4 filings revealing 17 insider transactions over the past 90 days, comprising 7 purchases and 10 sales. The net selling bias among corporate insiders suggests measured caution at current price levels. Dark pool activity scores 8.5 out of 25, reflecting below-average off-exchange institutional accumulation. Congressional trading activity registers at 5.1 out of 25, indicating limited legislative interest in ABT shares during the observed period. The divergence between strong institutional holdings and modest insider confidence creates a mixed smart money landscape, with no dominant directional signal emerging from aggregate positioning data.
Abbott Laboratories Earnings Outlook
Abbott Laboratories delivered modest earnings beats in its two most recently reported quarters, according to company earnings reports. The April 2026 quarter produced earnings per share of $1.15, exceeding the consensus estimate of $1.14 by $0.01. The July 2026 quarter showed continued outperformance with EPS of $1.31 versus an estimate of $1.28, representing a $0.03 positive surprise. Looking ahead, analyst estimates project EPS of $1.42 for each of the next two reporting periods, scheduled for October 2026, per consensus forecasts. The sequential step-up from $1.31 to an estimated $1.42 implies expected acceleration in earnings growth. Abbott's pattern of narrowly exceeding estimates across consecutive quarters demonstrates consistent operational execution, though the slim margins of surprise indicate that analyst models closely track the company's financial trajectory. Investors will focus on whether the projected $1.42 EPS target reflects sustainable momentum.
Wall Street Analyst Ratings for ABT
Wall Street coverage of Abbott Laboratories has turned increasingly constructive in recent months, according to analyst reports tracked by SID consensus data. On October 7, 2026, Barclays initiated coverage with an Overweight rating, adding a new bullish voice to the coverage universe. Rothschild & Co upgraded ABT to Buy from Neutral on October 2, 2026, reflecting improved conviction in the company's fundamental outlook. TD Cowen reiterated its Buy rating twice, on September 8 and August 25, 2026, maintaining a consistently positive stance. Wolfe Research upgraded shares to Outperform from Peer Perform on August 13, 2026, marking another notable sentiment shift. Across the five most recent analyst actions, all ratings fall on the positive side of the spectrum, with no holds or sell recommendations issued during this period. The convergence of upgrades and initiations at bullish ratings stands in contrast to the stock's 20.92% trailing twelve-month decline, suggesting analysts see valuation support at current levels.
